Loading...
•
Mar 31, 2021
Adverum Q1 2021 Earnings Report
Adverum reported financial results for the first quarter ended March 31, 2021.
Key Takeaways
Adverum Biotechnologies reported first quarter 2021 results, including license revenue of $7.5 million and a net loss of $28.4 million, or $0.29 per share. The company is focused on reviewing patient safety data from the ADVM-022 program and evaluating timelines and capital allocation priorities.
Management is focused on a thorough review of patient safety data from the ADVM-022 program.
Long-term data from the OPTIC trial demonstrated ADVM-022’s durability in patients with wet AMD.
A SUSAR of hypotony was announced in the INFINITY clinical trial, leading to a review of the ADVM-022 program data.
The company is evaluating timelines and capital allocation priorities to extend its cash runway.
Forward Guidance
Adverum is evaluating its timelines and capital allocation priorities with an aim to extend its cash runway beyond prior guidance.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...